Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)

Santen Pharmaceutical Co., Ltd.

Overview

This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for macular edema following branch retinal vein occlusion

Study Type

INTERVENTIONAL

Conditions

Macular Edema Following Branch Retinal Vein Occlusion

Interventions

Betamethasone Microsphere (DE-102） Low DoseDRUG

Betamethasone Microsphere (DE-102） High DoseDRUG

ShamDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 20 years of age or older * Diagnosis of macular edema following branch retinal vein occlusion Exclusion Criteria: * BCVA ETDRS letter score in non-study eye \< 35 * Known steroid-responder

Locations (2)

Santen study sites

Osaka, Japan

Santen study sites

Seoul, South Korea

Outcomes

Primary Outcomes

Change from baseline of Best Corrected Visual Acuity(BCVA) in ETDRS letter score

Secondary Outcomes

Change in retinal thickness from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.